Canada Markets closed

IntelGenx Technologies Corp. (IGX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5800+0.0100 (+1.75%)
At close: 3:12PM EDT

IntelGenx Technologies Corp.

6420 Abrams
Ville Saint Laurent
Montreal, QC H4S 1Y2
Canada
514 331 7440
http://www.intelgenx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Horst G. ZerbeChairman, CEO & Chairman of Scientific Advisory Board240.75kN/A1947
Mr. André Godin C.A., CPA, CPA, CAPres & CFO223.6kN/A1964
Ms. Nadine PaiementVice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp140.13kN/A1977
Dr. Dana MatzenVP of Bus. & Corp. Devel. of IntelGenx Corp171.43kN/A1978
Stephen KilmerInvestor Relations OfficerN/AN/AN/A
Dr. Rodolphe Obeid Ph.D.VP of Operations - IntelGenx CorpN/AN/A1980
Mr. Tommy Kenny J.D., L.L.B., M.Sc.VP of Intellectual Property & Legal Affairs and Gen. Counsel of IntelGenx CorpN/AN/A1987
Ms. Ingrid ZerbeCorp. Sec.N/AN/A1954
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Corporate Governance

IntelGenx Technologies Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.